PharmaCyte Biotech Releases Corporate Video
June 01 2015 - 7:48AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, today announced that it has launched a
new corporate video. In the video viewers will learn the PharmaCyte
Biotech story first hand through interviews and footage shot in
Singapore, Thailand, Sweden and Arizona.
PharmaCyte Biotech's Corporate Video can be viewed at
www.PharmaCyte.com/media.
The video documents PharmaCyte Biotech's live-cell encapsulation
technology, Cell-in-a-Box®, and how it is produced in Singapore and
Thailand. Viewers will learn of the technology's advantages over
other encapsulation technologies, improvements that have been made
to the technology since the first clinical trials and how
PharmaCyte Biotech will use Cell-in-a-Box® in treatments for
diabetes, cancer and symptoms related to solid cancerous tumors.
PharmaCyte Biotech's cancer and diabetes portfolios will also be
featured, complete with preclinical and clinical data highlighting
the technology's performance.
Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte
Biotech, said, "We are excited to present this video. This video
will take viewers right into each of the facilities that have been
and will be so instrumental in our success in both cancer and
diabetes. The rich footage and stellar interviews highlight what we
feel is a formidable story in the biotech industry."
Mr. Waggoner went on to say, "We have so many people to thank
for their time and participation in getting this documentary-like
video produced. First, we'd like to thank our partner, Austrianova,
and Prof. Walter H. Gunzburg, and Dr. Brian Salmons for letting us
spend time with them at their facilities in Singapore and Thailand.
We are grateful to Dr. Matthias Löhr for taking time out of his
extremely busy schedule to host us at the Karolinska Institute in
Stockholm, Sweden. Finally, we'd like to extend many thanks to the
entire team at Translational Drug Development (TD2) and Dr. Stephen
Gately, the Chief Executive Officer of TD2, for letting us spend a
couple of days at TD2's facility on the Mayo Clinic campus in
Scottsdale, Arizona."
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company
focused on developing and preparing to commercialize treatments for
cancer and diabetes based upon a proprietary cellulose-based live
cell encapsulation technology known as Cell-in-a-Box®. This unique
and patented technology will be used as a platform upon which
treatments for several types of cancer, including advanced,
inoperable pancreatic cancer, and diabetes are being built.
PharmaCyte Biotech's treatment for pancreatic cancer involves low
doses of the well-known anticancer prodrug ifosfamide, together
with encapsulated live cells, which convert ifosfamide into its
active or "cancer-killing" form. These capsules are placed as close
to the cancerous tumor as possible to enable the delivery of the
highest levels of the cancer-killing drug at the source of the
cancer. This "targeted chemotherapy" has proven remarkably
effective in past clinical trials.
PharmaCyte Biotech is also working towards improving the quality
of life for patients with advanced pancreatic cancer and on
treatments for other types of solid cancerous tumors. In addition,
PharmaCyte Biotech is developing treatments for cancer based upon
chemical constituents of the Cannabis plant, known as cannabinoids.
In doing so, PharmaCyte Biotech is examining ways to exploit the
benefits of Cell-in-a-Box® technology in optimizing the anticancer
effectiveness of cannabinoids, while minimizing or outright
eliminating the debilitating side effects usually associated with
cancer treatments. This provides PharmaCyte Biotech the rare
opportunity to develop "green" approaches to fighting deadly
diseases, such as cancer of the pancreas, brain and breast, which
affect hundreds of thousands of individuals worldwide every
year.
Safe Harbor
This press release may contain forward-looking statements
regarding PharmaCyte Biotech and its future events and results that
involve inherent risks and uncertainties. The words "anticipate,"
"believe," "estimate," "expect," "intend," "plan" and similar
expressions, as they relate to PharmaCyte Biotech or its
management, are intended to identify forward-looking statements.
Important factors, many of which are beyond the control of
PharmaCyte Biotech, could cause actual results to differ materially
from those set forth in the forward-looking statements. They
include PharmaCyte's ability to continue as a going concern, delays
or unsuccessful results in preclinical and clinical trials, flaws
or defects regarding its product candidates, changes in relevant
legislation or regulatory requirements, uncertainty of protection
of PharmaCyte Biotech's intellectual property and PharmaCyte
Biotech's continued ability to raise capital. PharmaCyte Biotech
does not assume any obligation to update any of these
forward-looking statements.
More information about PharmaCyte Biotech can be found at
www.PharmaCyte.com. It can also be obtained by contacting Investor
Relations.
CONTACT: Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: InvestorRelations@PharmaCyte.com